AsthmaMap: An interactive knowledge repository for mechanisms of asthma - 04/03/21
, Olga Ivanova, MSc a, d, e, Irina Balaur, PhD a, Marek Ostaszewski, PhD c, Valeriya Berzhitskaya, PhD f, Tatiana Serebriyskaya, PhD f, Thomas Ligon, PhD g, Jan Hasenauer, PhD h, i, Bertrand De Meulder, PhD a, Rupert W. Overall, PhD j, k, Ludovic Roy, MSc a, Richard G. Knowles, PhD l, Craig E. Wheelock, PhD m, Sven-Erik Dahlen, MD, PhD n, Kian Fan Chung, MD o, Ian M. Adcock, PhD o, Graham Roberts, DM p, q, Ratko Djukanovic, MD r, s, Johann Pellet, MSc a, Piotr Gawron, PhD c, Rudi Balling, PhD c, Anke H. Maitland-van der Zee, PharmD, PhD e, Reinhard Schneider, PhD c, Peter J. Sterk, MD e, Charles Auffray, PhD athe
U-BIOPRED Study Group,
theeTRIKS Consortium
Key words : Asthma, disease mechanisms, disease map, knowledge representation, data interpretation
Il testo completo di questo articolo è disponibile in PDF.
Mappa
| Disclosure of potential conflict of interest: S.-E. Dahlen reports personal fees from AstraZeneca, Boehringer-Ingelheim, Cayman Chemicals, GlaxoSmithKline (GSK), Novartis, Regeneron, Roche, Sanofi, and Teva outside the submitted work. K. F. Chung has received honoraria for participating in advisory board meetings of GSK, AstraZeneca, Roche, Novartis, Merck, BI, TEVA, and Shionogi regarding treatments for asthma, chronic obstructive pulmonary disease, and chronic cough and has also been remunerated for speaking engagements. R. Balling is a founder and a shareholder of MEGENO S.A. and a shareholder of ITTM S.A. R. Djukanovic reports receiving fees for lectures at symposia organized by Novartis, AstraZeneca, and TEVA; consultation for TEVA and Novartis as member of advisory boards; participation in a scientific discussion about asthma organized by GSK; and is a cofounder and current consultant and has shares in Synairgen, a University of Southampton spin-out company. A. H. Maitland-van der Zee reports grants and personal fees from Boehringer Ingelheim and GSK, grants from Vertex, and personal fees from AstraZeneca, all paid to her institution, and, in a public-private partnership, sponsored by Health Holland matching grants from Boehringer Ingelheim, Breathomix, Fluidda, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona, TopMD, and Novartis outside the submitted work. R. Schneider is a founder and a shareholder of MEGENO S.A. and ITTM S.A. P. J. Sterk is a scientific adviser and officially has a nonsubstantial interest in the start-up company Breathomix BV, which produces eNoses and accompanying cloud algorithms. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 147 - N° 3
P. 853-856 - marzo 2021 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
